Association between MDM2 promoter SNP309 T/G polymorphism and liver cancer risk-a meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2841-2846

  Ma, Hong Bo ^a   Huang, Tao ^a   Han, Feng ^a   Chen, Wei Yu ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Liver cancer; MDM2; Meta analysis; Polymorphism; Risk factor

Indexed keywords

EID: 84874006965     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2841     Document Type: Article

References (39)

1. Akkiz H, Sumbul AT, Bayram S, et al (2010). MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population. Cancer Epidemiol, 34, 448-52.
2. Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
3. Chen WQ (2009). Estimation of cancer incidence and mortality in China in 2004-2005. Chin J Cancer, 31, 664-8.
4. Cheok CF, Verma CS, Baselga J, et al (2011). Translating p53 into the clinic. Nat Rev Clin Oncol, 8, 25-37.
5. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
6. Deisenroth C, Zhang Y (2010). Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway. Oncogene, 29, 4253-60.
7. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
8. Dharel N, Kato N, Muroyama R, et al (2006). MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res, 12, 4867-71.
9. Di Vuolo V, Buonaguro L, Izzo F, et al (2011). TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer, 6, 13.
10. Ding C, Yu H, Qin H (2012). TP53 Codon 72 Polymorphism with Hepatocellular Carcinoma: a Metaanalysis. J Int Med Res, 40, 446-54.
11. Dongiovanni P, Fracanzani AL, Cairo G, et al (2010). Irondependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. Am J Pathol, 176, 1006-17.
12. Economopoulos KP, Sergentanis TN (2010). Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat, 120, 211-6.
13. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
14. El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27.
15. Embade N, Fernandez-Ramos D, Varela-Rey M, et al (2012). Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology, 55, 1237-48.
16. Ezzikouri S, El Feydi AE, Afifi R, et al (2009). MDM2SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev, 32, 380-5.
17. Ezzikouri S, Essaid El Feydi A, Afifi R, et al (2011). Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers, 26, 229-33.
18. Fang F, Yu XJ, Yu L, et al (2011). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol, 28, 981-5.
19. Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55.
20. Gajjar M, Candeias MM, Malbert-Colas L, et al (2012). The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell, 21, 25-35.
21. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
22. Hu Z, Jin G, Wang L, et al (2007). MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomark Prev, 16, 2717-23.
23. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
24. Jung CR, Lim JH, Choi Y, et al (2010). Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest, 120, 4493-506.
25. Kimman M, Norman R, Jan S, et al (2012). The Burden of Cancer in Member Countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20.
26. Lauria A, Tutone M, Ippolito M, et al (2010). Molecular modeling approaches in the discovery of new drugs for anticancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem, 17, 3142-54.
27. Leu JD, Lin IF, Sun YF, et al (2009). Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population.World J Gastroenterol, 15, 5592-7.
28. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
29. Muellerleile P, Mullen B (2006). Sufficiency and stability of evidence for public health interventions using cumulative meta-analysis. Am J Public Health, 96, 515-22.
30. Stommel JM, Wahl GM (2005). A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle, 4, 411-7.
31. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology. JAMA, 283, 2008.
32. Wang B, Huang G, Wang D, et al (2010). Null genotypes of GSTM1 and GSTT1 contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. J Hepatol, 53, 508-18.
33. Wang X, Zhang X, Qiu B, et al (2012). MDM2 SNP309T>G polymorphism increases susceptibility to hepatitis B virusrelated hepatocellular carcinoma in a northeast Han Chinese population. Liver Int, 32, 1172-8.
34. Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107.
35. Wiangnon S, Kamsa-Ard S, Suwanrungruang K, et al (2012). Trends in incidence of hepatocellular carcinoma, 1990 - 2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8.
36. Wilkening S, Bermejo JL, Hemminki K (2007). MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 28, 2262-7.
37. Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6.
38. Zhang MF, Zhang ZY, Fu J, et al (2009). Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma. J Transl Med, 7, 110.
39. Zintzaras E, Lau J (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol, 61, 634-45.